Brimonidine Ophthalmic Dosing in Adults and Children
Brimonidine 0.2% ophthalmic solution should be dosed as one drop in the affected eye(s) three times daily, approximately 8 hours apart, in adults with glaucoma or ocular hypertension, but should be avoided entirely in children under 2 years of age and used with extreme caution in young children due to serious risk of CNS depression including apnea, bradycardia, and hypotension. 1, 2, 3
Adult Dosing
Standard Regimen:
- One drop of brimonidine 0.2% in the affected eye(s) three times daily, spaced approximately 8 hours apart 1
- When using with other topical ophthalmic medications, wait at least 5-10 minutes between different drops to prevent washout and ensure proper absorption 4, 5
- Instruct patients on eyelid closure or nasolacrimal occlusion after instillation to reduce systemic absorption 4
Clinical Efficacy:
- Mean IOP reductions of 5.6-5.9 mm Hg at peak (2 hours post-dose) and 3.3-3.7 mm Hg at trough (12 hours post-dose) with brimonidine 0.2% twice daily 6
- Efficacy comparable to timolol 0.5% at peak measurements and superior to betaxolol 0.25% at both peak and trough 6
Pediatric Considerations: Critical Safety Warnings
Contraindications and Extreme Caution:
- Brimonidine is contraindicated in infants and should be avoided in children under 2 years of age due to severe CNS toxicity risk 7, 8
- Brimonidine crosses the blood-brain barrier and causes serious adverse effects in young children including apnea, somnolence, bradycardia, hypotension, hypothermia, and hypotonia 2, 7, 8
Documented Pediatric Toxicity:
- Two children aged 2.4 and 3.7 years experienced repeated episodes of being unarousable after brimonidine administration 7
- Five additional children experienced extreme fatigue requiring discontinuation 7
- A 6-week-old infant developed bradycardia and hypotension following brimonidine 0.15% administration 8
- All symptoms resolved after discontinuation 7
Age-Related Dosing Concerns:
- Brimonidine is not dosed by weight, placing pediatric patients at increased risk for systemic toxicity 8
- In older children (mean age 10.5 years), brimonidine showed modest IOP reduction of 6.7% but required careful monitoring 7
- Use only in selected older pediatric patients when benefits clearly outweigh risks, with close monitoring for CNS effects 7
Special Populations
Pregnancy:
- Brimonidine has FDA Pregnancy Category B rating (safer than most glaucoma medications which are Category C) 3, 4, 5
- Beta-blockers are typically preferred during pregnancy due to longer safety experience 2, 3
Breastfeeding:
- Brimonidine should not be used in breastfeeding mothers due to risk of apnea and somnolence in nursing infants 2, 3, 4
- Brimonidine is detected in breast milk and crosses the blood-brain barrier in infants 2, 3
Cardiovascular Disease:
- Unlike beta-blockers, brimonidine is not contraindicated in patients with cardiopulmonary disease, asthma, or COPD 4, 6, 9
- Use with caution in severe cardiovascular disease, though clinically significant changes in blood pressure and heart rate are uncommon 6
Combination Therapy
With Other Glaucoma Medications:
- Brimonidine may be used concomitantly with other topical ophthalmic drugs to lower IOP 1
- Has additive IOP-lowering effects when combined with beta-blockers or carbonic anhydrase inhibitors 4, 5, 10
- Fixed combination brimonidine/timolol provides superior IOP reduction compared to monotherapy with either component 10
Common Adverse Effects in Adults
Most Frequent:
- Oral dryness (30% of patients) 6
- Ocular hyperemia (26.3%) 6
- Ocular burning/stinging (24%) 6
- Ocular allergic reactions including allergic blepharitis and follicular conjunctivitis (9.6%) 6
Monitoring Requirements
Follow-up Schedule: